Upper Respiratory Tract Disease Treatment Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030

The global Upper Respiratory Tract Disease Treatment market is anticipated to grow at a CAGR of 3.6% during the forecast period (2023-2030). Growing Incidence of several types of Upper Respiratory Tract Infections. One of the most common URTI which is RSV is a highly contagious virus that causes infections of the lungs and breathing passages in individuals of all age groups. RSV circulation is seasonal, typically starting during the fall and peaking in the winter. In older adults, RSV is a common cause of lower respiratory tract disease (LRTD), which affects the lungs and can cause life-threatening pneumonia and bronchiolitis (swelling of the small airway passages in the lungs). According to the U.S. Centers for Disease Control and Prevention, each year in the U.S., RSV leads to approximately 60,000-120,000 hospitalizations and 6,000-10,000 deaths among adults 65 years of age and older. Owing to which government and FDA are giving approvals. For an instance, in May 2023, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/upper-respiratory-tract-disease-treatment-market

Another factor supporting the market growth is attributed to the growing effect of combination therapies. which combine two or more bronchodilator inhaler medications, are becoming increasingly common as they provide better therapeutic results and are more convenient for patients. For instance, in August 2020, Teva Pharmaceutical Industries Ltd. announced ProAir Digihaler (albuterol sulfate 117 mcg) Inhalation Powder, the first and only digital rescue inhaler approved for use in patients four years of age and older for the treatment or prevention of bronchospasm in those with reversible obstructive airway disease, as well as for the avoidance of exercise-induced bronchospasm (EIB).

Market Coverage

• The market number available for - 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Category
o By Treatment
o By Drug class
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes F. Hoffmann-La Roche Ltd, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company and others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Upper Respiratory Tract Disease Treatment Market Report Segment

By Category

• OTC
• Prescription

By Treatment

• Topical treatment
• Cough Suppressant
• Nasal Decongestant
• Others (Antihistamines, Guaifenesin, and Cromolyn)

By Drug class

• NSAID
• Antibiotics
• Others (Ibuprofen)

A full report of Upper Respiratory Tract Disease Treatment Market available @ https://www.omrglobal.com/industry-reports/upper-respiratory-tract-disease-treatment-market

Global Upper Respiratory Tract Disease Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Alcon, Inc.
• AstraZeneca Plc
• Cipla Limited
• CSL Ltd.
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Lupin Limited
• Market positioning of vendors
• Merck & Co., Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Sandoz, Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.